# Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

> **NCT05722912** · — · APPROVED_FOR_MARKETING · sponsor: **Incyte Corporation**

## Conditions studied

- Graft-versus-host Disease (GVHD)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05722912
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05722912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05722912, "Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05722912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*